Clinical trials: Influenza, completed
Pregnancy, Influenza
Maternal Immunization: Giving Immunity For Tomorrow
Study objectives are to compare influenza antibody levels in infant sera and maternal colostrum or breast milk at delivery, 2, and 6 months women who receive influenza immunization in early pregnancy, late pregnancy, or no…
- Trial name
- MI GIFT (NCT01496079)
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- University of Utah
Influenza
Protection From Influenza: Determining the Impact of Prior Infection
The investigators propose a unique methodology of studying infection and vaccination history and immune responses. As most studies in infection history are conducted on mice, limitations are inherent on their applicability to…
- Trial name
- NCT03004040
- Testing
- Flu Vaccine
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Health Sciences North Research Institute
Influenza, Human
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
This is a safety and Immunogenicity first-in-human dose-ranging study of self-amplifying RNA Seasonal Influenza Vaccine (ARCT-2138) in adults.
- Trial name
- NCT06125691
- Testing
- ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults
- Where
- 2 sites in Australia
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Upper Respiratory Infections, Influenza
Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections
The aim of the study was to assess the effectiveness of a hand-washing programme using hand sanitizer in the prevention of school absenteeism due to upper respiratory infections.
- Conditions
- Upper Respiratory Infections, Influenza, Common Cold
- Trial name
- NCT01728090
- Testing
- hand sanitizer
- Volunteers
- 1,640 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Influenza
Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization
The purpose is to investigate B-cell response to the trivalent Influenza Vaccine (TIV) in healthy young adults by vaccinating participants and obtaining blood samples at designated time points before and after vaccination.
- Trial name
- SLVP023 (NCT02987374)
- Testing
- 2011-2012 Fluzone IIV3 (IM)
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel
This randomized, open-label, active-controlled trial will assess humoral immune responses to a single dose of 2019-20 recombinant hemagglutinin quadrivalent influenza vaccines (RIV4) compared with standard egg-based unadjuvanted…
- Trial name
- NCT04523324
- Testing
- Flublok™ Quadrivalent by Sanofi, Inc., VaxigripTetra™ by Sanofi, Inc.
- Where
- 2 sites in Israel
- Volunteers
- 577 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Influenza
Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus
This is a non-controlled, open-label, single-center, dose-escalation study to determine the safety, infectivity, and immune responses elicited from of the potential influenza virus challenge strain.
- Trial name
- NCT04106817
- Testing
- Live, wild-type A/California/H1N1 2009 influenza virus
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- WCCT Global
Influenza
T and B Cell Response to Avian Flu Vaccine
The purpose of this substudy study is to evaluate the types of cells involved in fighting infection to the A/H5N1 (avian flu virus) vaccine.
- Trial name
- NCT00337896
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008
Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO and CPMP recommendations.
- Trial name
- NCT00518453
- Testing
- Surface antigen inactivated influenza vaccine
- Where
- United Kingdom
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
To describe the safety findings from Days 0 to 44 following injection of the 2003-2004 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule in accordance with the…
- Trial name
- NCT00836953
- Testing
- Influenza virus vaccine (Pediatric formulation)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers, Influenza
Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
Background: Seasonal influenza is a major health problem whose impact is typically reduced by vaccination. The H1N1 (swine flu) influenza virus is an emerging pathogen that has the potential to cause devastating illness and even…
- Trial name
- NCT01191853
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pneumococcal Infection, Influenza
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
The 23-valent pneumococcal Polysaccharide vaccine (23vPPV) has been developed for children and adults to prevent pneumococcal diseases such as pneumonia (inflammation of the lungs), meningitis (inflammation of the brain lining)…
- Trial name
- NCT02062281
- Testing
- 23-valent pneumococcal polysaccharide vaccine, trivalent influenza vaccine, 23vPPV+TIV
- Where
- China
- Volunteers
- 2,225 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
The purpose of this study was to determine the safety and descriptive immunogenicity of the H1N1 influenza vaccine in healthy children.
- Trial name
- MI-CP217 (NCT00946101)
- Testing
- MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]
- Where
- 16 sites in United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Flu, Human
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years
Comparative assessment of the tolerability, safety, and immunogenicity of the Flu-M® Inactivated Split Influenza Vaccine (without preservative) and the Flu-M® vaccine (with preservative) in volunteers aged between 18 and 60
- Trial name
- NCT05312294
- Testing
- Flu-M [inactivated split influenza vaccine] without preservative, Flu-M [inactivated split influenza vaccine] with preservative
- Where
- 8 sites in Russia
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Healthy
Immune and Hormone Response to Influenza Vaccine
The purpose of this pilot research project is to look at the effect of the inactivated influenza vaccine (seasonal flu shot) on early signs of immune or germ-fighting response known as cytokines or signal molecules.
- Trial name
- NCT01978262
- Testing
- Seasonal Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Influenza
Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza
The purpose of this study is: to assess clinical efficiency of Ergoferon for treatment of influenza to assess safety of Ergoferon for treatment of influenza to compare efficiency of Ergoferon and Tamiflu for treatment of influenza
- Trial name
- NCT01804946
- Testing
- Ergoferon, Oseltamivir
- Where
- 8 sites in Russia
- Volunteers
- 161 people
- Sponsor
- Materia Medica Holding
Mobile Apps, Immunization
Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform
Methods Study Procedures A two-centred randomized control trial (RCT) was conducted to evaluate the use of safety reporting via a mobile app compared to safety reporting via web-based CANVAS notifications amongst individuals…
- Conditions
- Mobile Apps, Immunization, Adverse Event Following Immunisation
- Trial name
- NCT05794113
- Testing
- Mobile app - CanImmunize, Web based notification
- Where
- Canada
- Volunteers
- 2,408 people, healthy volunteers welcome
- Sponsor
- The Ottawa Hospital
Influenza
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
The present study OVX836-006 aims principally to: Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e.
- Trial name
- NCT05734040
- Testing
- OVX836 480µg, Fluarix Tetra, Afluria Quad
- Where
- 9 sites in Australia
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza
A Study to Assess the PK of AL-794 Formulations in Healthy Subjects
This study is a single-center, randomized, open-label crossover study to assess the pharmacokinetics and food effect of AL-794 formulations in healthy subjects.
- Trial name
- NCT02877160
- Testing
- AL-794 suspension, AL-794 tablet
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Human Influenza
Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine
Phase III clinical trial was carried out in Jintan city, Jiangsu Province, China in May, 2006. Trial results showed that the vaccine had proved safety and immunogenicity.
- Trial name
- NCT01568788
- Testing
- Inactivated Influenza Vaccine, Inactivated Influenza Vaccine of Pasteur, Inactivated Influenza Vaccine of GSK
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.